Search CTL/CD8+ T-Cell Epitope Database

Found 4 matching records:

Displaying record number 56194

Download this epitope record as JSON.

HXB2 Location	Pol(67-76) Protease(11-20) DNA(2283..2312)	Pol Epitope Map
Author Location	Pol(98-)
Epitope	VTIKIGGQLK	Epitope Alignment
Species (MHC/HLA)	human(A*03:01)
Immunogen	vaccine
Country	Botswana, United States
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay
Keywords	vaccine antigen design

Vaccine Details

Notes

• This is a trial of a multi-epitope DNA vaccine that included 21 CTL epitopes, which are conserved among clades A,B,C,D and CRFs and are supertype binding peptides of A1, A3 and B7 supertypes. Participants were from US and Botswana.
• The vaccine was safe and well-tolerated, but the rate of CTL induction was low. CD8+ responses (and no CD4+ responses) were detected in 3/26 subjects using chromium release assay and in 2/42 subjects using IFN-γ ELISPOT assay.
• This epitope was included in the vaccine.

References

Gorse2008a Geoffrey J. Gorse, Lindsey R. Baden, Margaret Wecker, Mark J. Newman, Guido Ferrari, Kent J. Weinhold, Brian D. Livingston, Tonya L. Villafana, Hongli Li, Elizabeth Noonan, Nina D. Russell, and HIV Vaccine Trials Network. Safety and Immunogenicity of Cytotoxic T-Lymphocyte Poly-Epitope, DNA Plasmid (EP HIV-1090) Vaccine in Healthy, Human Immunodeficiency Virus Type 1 (HIV-1)-Uninfected Adults. Vaccine, 26(2):215-223, 10 Jan 2008. PubMed ID: 18055072. Show all entries for this paper.

Displaying record number 53068

Download this epitope record as JSON.

HXB2 Location	Pol(67-76) Protease(11-20) DNA(2283..2312)	Pol Epitope Map
Author Location	Pol
Epitope	VTIKIGGQLK	Epitope Alignment
		Show epitope variants
Epitope Name	Pol 98
Subtype	M group
Species (MHC/HLA)	human, humanized mouse, mouse(A*11:01)
Immunogen	in vitro stimulation or selection, vaccine
Experimental methods	Cytokine production, T-cell Elispot
Keywords	subtype comparisons, computational epitope prediction, escape, TCR usage, variant cross-reactivity

Vaccine Details

Notes

• This study examined variant recognition of epitopes presented by A*0201 and A*1101. Numerous amino acid substitutions can be introduced into epitopes without disrupting their recognition by CTLs, although epitopes with multiple substitutions were less recognized. An algorithm was constructed for prediction of epitopes capable of inducing responses to a great number of variant epitopes.
• A total of 30 variant forms of Pol 98 were identified. 50% of the variant epitopes were recognized by CTLs from mice immunized with the parental form.
• Pol 98 epitope was present in 71% of HIV sequences of many M group subtypes.

References

McKinney2004 Denise M. McKinney, Rhonda Skvoretz, Brian D. Livingston, Cara C. Wilson, Michelle Anders, Robert W. Chesnut, Alessandro Sette, Max Essex, Vladimir Novitsky, and Mark J. Newman. Recognition of Variant HIV-1 Epitopes from Diverse Viral Subtypes by Vaccine-Induced CTL. J. Immunol., 173(3):1941-1950, 1 Aug 2004. PubMed ID: 15265928. Show all entries for this paper.

Displaying record number 56536

Download this epitope record as JSON.

HXB2 Location	Pol(67-76) Protease(11-20) DNA(2283..2312)	Pol Epitope Map
Author Location	Pol
Epitope	VTIKIGGQLK	Epitope Alignment
Epitope Name	Pol98
Subtype	B
Species (MHC/HLA)	human(A3)
Immunogen	vaccine
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	vaccine antigen design

Vaccine Details

Notes

• DNA vaccine EP HIV-1090 evaluation in patients receiving ART was done. This vaccine is composed of multiple CTL epitopes, all associated with certain HLA supertypes. Differences of CTL response rate in vaccine and placebo recipients however, was not significant.
• VTIKIGGQLK is a Pol epitope encoded in the EP HIV-1090 polyepitope vaccine.

References

Wilson2008 Cara C. Wilson, Mark J. Newman, Brian D. Livingston, Samantha MaWhinney, Jeri E. Forster, Jim Scott, Robert T. Schooley, and Constance A. Benson. Clinical Phase 1 Testing of the Safety and Immunogenicity of an Epitope-Based DNA Vaccine in Human Immunodeficiency Virus Type 1-Infected Subjects Receiving Highly Active Antiretroviral Therapy. Clin. Vaccine Immunol., 15(6):986-994, Jun 2008. PubMed ID: 18400976. Show all entries for this paper.

Displaying record number 56516

Download this epitope record as JSON.

HXB2 Location	Pol(67-76) Protease(11-20) DNA(2283..2312)	Pol Epitope Map
Author Location	Pol
Epitope	VTIKIGGQLK	Epitope Alignment
Epitope Name	Pol98
Subtype	B, C, D
Species (MHC/HLA)	human, mouse(A3 supertype)
Immunogen	HIV-1 infection
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	binding affinity, supertype, vaccine-induced immune responses, HLA cross-presentation

Notes

• 21 supertype-A2, -A3 and -B7-restricted epitopes predicted to be immunogenic by HLA-peptide binding motifs and phenotypic frequency in individuals were recognized by HIV-1+ subjects in ELISpot assays and shown to bind with high affinity to minimum 3 HLA-alleles of the restricting supertype. These epitopes were included in DNA vaccine EP HIV-1090 that avoided immunodominant responses and did not restrict subject immunity to predicted HLA-type when tested in mice. Transgenic mice mounted a vaccine-response similar to that induced by ELISpot assay in humans.
• Epitope VTIKIGGQLK of the HLA-A3 supertype bound most strongly to HLA-A*1101, and -A*6801 and also to -A*0301 but not to -A*3301 or -A*3101. It was conserved 63% in subtype B, 13% in C and 50% in subtype D. 4/23 HLA-A3 supertype expressing HIV-1+ subjects mounted a positive ELISpot response to Pol98.

References

Wilson2003 Cara C. Wilson, Denise McKinney, Michelle Anders, Samantha MaWhinney, Jeri Forster, Claire Crimi, Scott Southwood, Alessandro Sette, Robert Chesnut, Mark J Newman, and Brian D Livingston. Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1. J. Immunol., 171(10):5611-5623, 15 Nov 2003. PubMed ID: 14607970. Show all entries for this paper.